Propanc Biopharma, Inc. announces a shareholder update from CEO Mr. James Nathanielsz. The company highlights progress in 2025 and ambitious plans for 2026, focusing on developing treatments for chronic diseases, including cancer. The lead asset, PRP, a fixed-dose combination of proenzymes, will advance into a Phase 1b clinical study in Melbourne, Australia. Propanc invests over $30 million in research, with PRP showing potential in selectively targeting cancer cells. The company also expands research into treating fibrosis and develops a fully synthetic backup compound, Rec-PRP, for improved efficacy and room-temperature stability. Propanc remains focused on long-term value creation and scientific progress.

Read more at GlobeNewswire: Propanc Biopharma Provides Shareholder Update